KNOWLEDGE BANK

Interviews

Thomson Reuters

Senior Vice President
We believe publications such as Pharmafocus Asia are essential in providing professionals with insights into the dynamic and evolving trends of the Pharma industry

Articles

Therapeutic Peptides

Therapeutic peptides are a promising frontier in precise medicine leveraging unique properties for targeted treatment Advancements in production modification and delivery have surmounted challenges Originating from human hormones and natural sources peptides hold potential for various conditions including cardiovascular diseases

Research Insights

An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile

Abstract We analyze the patent filing strategies of foreign pharmaceutical companies in Chile distinguishing between primary active ingredient and secondary patents patents on modified compounds formulations dosages particular medical uses etc There is prior evidence that secondary patents are used by pharmaceutical originator c

Case Studies

Evaluation of A Sequencing Batch Reactor Sewage Treatment Rig For Investigating The Fate of Radioactively Labelled Pharmaceuticals: A Case Study of Propranolol

Abstract Pharmaceuticals are frequently detected in the aquatic environment and have potentially damaging effects Effluents from sewage treatment plants STPs are major sources of these substances The use of sequencing batch reactor SBR STPs involving cycling between aerobic and anoxic conditions to promote nitrification and denitrification is increasin

Techno Trends

Janssen Pharmaceutical Discovered First-of-its-Kind ERLEADA® (apalutamide)

The Janssen Pharmaceutical Companies of Johnson Johnson discovered firstofitskind ERLEADA apalutamide for the treatment of patients with nonmetastatic castrationresistant prostate cancer nmCRPC and for the treatment of patients with metastatic castrationsensitive prostate cancer mCSPC

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Kinase Inhibitors as Antiviral Agents

Thanigaimalai Pillaiyar

Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.

 

Stefan Laufer

Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.

 

2

Accelerating the Medical Writing Process with Automation From research to publication

Nirupama Parate

Nirupama Parate a Senior Associate at Freyr Solutions’ Medicinal Products Division is an MBA Pharmaceutical Tech graduate and has a knack for Medical Writing Automation. She holds experience across pharmaceutical and medical devices ranging from Regulatory Affairs, pharmaceutical marketing and communications, and medical writing automation. She strongly believes in walking the extra mile and adding a personal touch to everything she does.

 

3

Novel Developments in Drug Delivery Systems

Saina Bijanzadeh

Saina Bijanzadeh is a chemist specializing in nanomaterial-based drug delivery and biomedical applications. She has research experience in nanoparticle synthesis, MOF platforms, and drug release systems, with published work in international journals. Her interests focus on innovative therapeutic delivery strategies and interdisciplinary pharmaceutical and bio(medical)engineering research.

4

Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

Dr. Stevan Pecic

Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.

 

Xiaohui Weng

Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.

 

Michael Gonzalez

Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.

 

Arya Emami

Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.

Dr. Amir Barzegar Behrooz

Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.

 

Dr. Rui Vitorino

Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.

 

Dr. Saeid Ghavami

Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.

 

5

Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2

Sinosh Skariyachan

Sinosh Skariyachan Ph.D. is presently working as Assistant Professor in Microbiology at St. Pius X College, Rajapuram  (Aided by Govt. of Kerala, India), Kasaragod, Kerala, India with more than 17 years of experience in teaching and research. One of his key areas of research is computational drug discovery and medicinal chemistry. He has published more than 75 international papers, book chapters, and text books. He is the editor of prestigious journals such as Computers in Biology and Medicine (Elsevier), Frontiers in Microbiology and a referee for more than 125 international journals. He received several awards and grants.

 

press releasesRead more...

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy

HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases

HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation

Cotecna Group Acquires Energon Labs

Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...

Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus

Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...

EventsRead more...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

LATEST NEWSRead more...

UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis

UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies

Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ

Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals

Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours

Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...

Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases

Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...

Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors

Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...